2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Radionuclide-Drug Conjugates (RDCs)
  5. Radionuclide-Drug Conjugates (RDCs) Isoform

Radionuclide-Drug Conjugates (RDCs)

 

Radionuclide-Drug Conjugates (RDCs) Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-159768A
    DOTAGA.Glu.(FAPi)2
    DOTAGA.Glu.(FAPi)2 is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging or therapy.
  • HY-159767A
    (S)-DOTAGA.(SA.FAPi)2
    (S)-DOTAGA.(SA.FAPi)2 is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging or therapy.
  • HY-159770A
    (S)-EB-FAPI-B2
    (S)-EB-FAPI-B2 (Compound II-11) is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging or therapy.
  • HY-167830
    SDM-8
    SDM-8 is a PET Radiopharmaceutical. SDM-8 shows high SV2A binding affinity with a Ki of 0.58 nM. SDM-8 can be used in the study of Alzheimer's disease.